SUFYAN BINMAHFOOZ: Open Payments
NPI 1558070607 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,060 in 46 payments from 12 companies in 2025. Trend: 2023 $111 · 2024 $806 · 2025 $1,060
Food & beverage: $1,060
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $209 |
| ViiV Healthcare Company | 6 | $181 |
| PFIZER INC. | 9 | $169 |
| Gilead Sciences, Inc. | 7 | $159 |
| Lilly USA, LLC | 5 | $103 |
| Merck Sharp & Dohme LLC | 2 | $57 |
| Boston Scientific Corporation | 2 | $51 |
| Novo Nordisk Inc | 2 | $48 |
| SANOFI PASTEUR INC. | 1 | $31 |
| Phadia US Inc. | 1 | $21 |
Products named: APRETUDE, MOUNJARO, PREVNAR 20, NURTEC ODT, UBRELVY, LO LOESTRIN FE, QULIPTA, GARDASIL 9.
Industry payments across DC — which companies pay providers there.
